HeyJaredAI Live
Join Dr. Gideon Kwok, DO and Lori Robertson, MSN, FNP-C of The Aesthetic Immersion as they discuss everything aesthetics and aesthetics business & continuing education related.
- Indexed episodes, last 90 days
- 3
- Latest publication
- Sep 3, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 16, 2026
Latest episodes
Ai Live | Good Faith Exams (opens the original)
Read excerpt
Explore the crucial topic of good faith exams and legal safety in medical aesthetics clinics. This episode breaks down current regulations, practical protocols, and key considerations for providers and nurses in the field. • Why good faith exams are required for nurses and how they differ from standing orders • State-by-state variation in aesthetic medicine laws and importance of board research • Best practices for documentation, verbal orders, and protecting your license • Policy and procedure
Ai Live | Obagi Saypha® MagIQ™ - Rethinking Filler Performance (opens the original)
Read excerpt
Most injectors today aren’t struggling with technique—they’re navigating choice. With so many fillers promising similar outcomes, the real challenge is understanding what actually performs differently once it’s in the tissue. Integration, adaptability, movement, longevity—these aren’t just product claims, they’re what define your results. As aesthetics evolves, so does the expectation: not just to inject well, but to choose smarter. ⚡ Enter Obagi Saypha® MagIQ™—a next-generation HA filler design
AI Live | Let’s Talk About Boey®: The Rapid-Onset, Short-Duration Neurotoxin (opens the original)
Read excerpt
Join Lori and Gideon as they dive into the latest developments in the aesthetic medicine industry. This episode covers recent travel, new neurotoxin updates, top training opportunities, and key industry insights. - News on Boey (botulinum toxin type E): rapid onset, short duration, and its approval status - Practical discussion of pricing, safety, and dosing strategies for neurotoxins - Comparison of toxins: Dysport, Botox, Jeuveau, Letybo, and implications for resistance - Upcoming training eve
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.